Olink Proteomics
Developing technology for human protein biomarker research
Company details
Year Aquired
2019
Location
Uppsala, Sweden
Revenue
NA
Sector
Life Science
Employees
Investment Themes
Changing Demographics
Contact
If you want to know more about Olink Proteomics please contact Tommi Unkuri at: tommi.unkuri@summaequity.com
Website
Olink has a unique technology for protein analysis in human protein biomarker research for a more efficient and precise analysis of large numbers of proteins. This technology drives precision medicine by improving the understanding of the interaction of proteins and human disease which is key to improve treatment and patient outcomes across many disease areas.
Challenge
The field of proteomics has been determined to be one of the most important research areas to fully understand and characterize disease. However, the scientific community has lacked strong technologies and solutions to advance this research over the past decades.
How do we solve it?
Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to analyse large numbers of proteins with high-throughput analysis, exceptional data quality, and minimal sample consumption. This enables research that previously could not be done.
How do we improve?
Over the next few years, Olink will scale up operations across markets and applications to drive significant benefits for customers, patients and the research community worldwide.
Value creation
Olink has experienced rapid growth in recent years and will continue to see high growth for years to come. The company will focus on building an organization that can support the growing global demand from an continuously expanding customer base, as well as continue development of its technology to address additional applications within proteomics.
Year Aquired
2019
Revenue
NA
Employees
Investment Themes
Changing Demographics
Sector
Life Science
Location
Uppsala, Sweden
Contact
If you want to know more about Olink Proteomics please contact Tommi Unkuri at: tommi.unkuri@summaequity.com
Website
Video
Learn more about EcoOnline
Portfolio Story
Olink Proteomics AB announce acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays
Dear Friends, UPPSALA, Sweden, May 12, 2020 – Olink today announced the acquisition of Agrisera AB, a Swedish company specializing in polyclonal and monoclonal antibody production. Agrisera offers an extensive collection of primary and secondary antibodies for a broad range of applications, available in various quantities. The acquisition is an important milestone for Olink in its…
Portfolio Story
Summa Equity acquires Olink Proteomics
Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. Summa Equity is excited to support this development, and to…
Updated:
Olink Proteomics AB announce acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays
Updated: